SENATE 204115th CongressBecame Public Law No: 115-176.

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017

Last Action: 5/30/2018

Actions

2018-05-30Became Public Law No: 115-176.
2018-05-30Became Public Law No: 115-176.
2018-05-30Signed by President.
2018-05-30Signed by President.
2018-05-24Presented to President.
2018-05-24Presented to President.
2018-05-22Motion to reconsider laid on the table Agreed to without objection.
2018-05-22On passage Passed by recorded vote: 250 - 169 (Roll no. 214). (text: CR H4355-4356)
2018-05-22Passed/agreed to in House: On passage Passed by recorded vote: 250 - 169 (Roll no. 214).(text: CR H4355-4356)
2018-05-22On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 231 (Roll no. 213).
2018-05-22The previous question on the motion to recommit with instructions was ordered without objection.
2018-05-22DEBATE - The House proceeded with 10 minutes of debate on the motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to strike everything after section 1 and insert a completely new text.
2018-05-22Ms. Schakowsky moved to recommit with instructions to the Committee on Energy and Commerce. (CR H4363)
2018-05-22The previous question was ordered pursuant to the rule.
2018-05-22DEBATE - The House proceeded with one hour of debate on S. 204.

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2018-05-30 (49)

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must report annually to the Food and Drug Administration (FDA) on any use of the drug in accordance with these provisions. The FDA shall post an annual summary report of such use on its website.

The bill limits the liability of a sponsor, manufacturer, prescriber, or dispenser that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.

Cosponsors (20)

John Barrasso (R-WY)
Roy Blunt (R-MO)
John Boozman (R-AR)
Shelley Capito (R-WV)
Thad Cochran (R-MS)
Bob Corker (R-TN)
Tom Cotton (R-AR)
Mike Crapo (R-ID)
Ted Cruz (R-TX)
Steve Daines (R-MT)
Joe Donnelly (D-IN)
MICHAEL ENZI (R-WY)
Deb Fischer (R-NE)
JEFF FLAKE (R-AZ)
Cory Gardner (R-CO)
Lindsey Graham (R-SC)
Charles Grassley (R-IA)
ORRIN HATCH (R-UT)
Dean Heller (R-NV)
John Hoeven (R-ND)

Subjects

Civil actions and liability
Drug safety, medical device, and laboratory regulation
Drug therapy
Health technology, devices, supplies
Long-term, rehabilitative, and terminal care
Prescription drugs
Product safety and quality

Became law: Pub. L. 115-176

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.